CBTRUS统计报告:2013-2017年美国原发性脑及其他中枢神经系统肿瘤
美国脑肿瘤登记处(CBTRUS)联合CDC和NCI发布2013-2017年基于全美人群的原发性脑及中枢神经系统肿瘤统计报告。所有恶性与非恶性脑及中枢神经系统肿瘤的平均年年龄调整发病率为23.79/10万,其中恶性为7.08/10万,非恶性为16.71/10万。恶性脑及中枢神经系统肿瘤的5年相对生存率为23.5%,非恶性为82.4%。
要点
- 全美恶性与非恶性脑及中枢神经系统肿瘤的平均年年龄调整发病率为23.79/10万。
- 胶质母细胞瘤是最常见的恶性肿瘤(占全部肿瘤的14.5%),脑膜瘤是最常见的非恶性肿瘤(占38.3%)。
- 恶性脑及中枢神经系统肿瘤的5年相对生存率为23.5%,非恶性为82.4%。
核心结论
- 全美恶性与非恶性脑及中枢神经系统肿瘤的平均年年龄调整发病率为23.79/10万。
- 胶质母细胞瘤占全部肿瘤的14.5%,脑膜瘤占全部肿瘤的38.3%。
- 恶性脑及中枢神经系统肿瘤的5年相对生存率为23.5%,非恶性为82.4%。
研究设计与样本
- CBTRUS与CDC和NCI合作,基于覆盖全美人群的最大人群登记数据,发布2013-2017年原发性脑及中枢神经系统肿瘤统计报告。
- 所有发病率和死亡率均按2000年美国标准人口进行年龄调整,以每10万人口表示。
主要发现
- 全部恶性与非恶性脑及中枢神经系统肿瘤的平均年年龄调整发病率为23.79/10万(恶性7.08/10万,非恶性16.71/10万)。
- 女性发病率高于男性(26.31 vs 21.09),黑人高于白人(23.88 vs 23.83),非西班牙裔高于西班牙裔(24.23 vs 21.48)。
- 儿童和青少年(0-19岁)全部原发性脑及中枢神经系统肿瘤的发病率为6.14/10万。
- 2013-2017年间恶性脑及中枢神经系统肿瘤死亡81,246例,平均年死亡率为4.42/10万。
- 2020年美国预计新诊断恶性与非恶性脑及中枢神经系统肿瘤83,830例(恶性24,970例,非恶性58,860例)。
关键数值与推荐
- 全部恶性与非恶性脑及中枢神经系统肿瘤的平均年年龄调整发病率为23.79/10万。
- 恶性脑及中枢神经系统肿瘤的平均年年龄调整发病率为7.08/10万,非恶性为16.71/10万。
- 胶质母细胞瘤占全部肿瘤的14.5%,脑膜瘤占全部肿瘤的38.3%。
- 恶性脑及中枢神经系统肿瘤的5年相对生存率为23.5%,非恶性为82.4%。
- 2013-2017年恶性脑及中枢神经系统肿瘤平均年死亡率为4.42/10万。
临床怎么用
- 可为神经外科医生提供美国原发性脑及中枢神经系统肿瘤的发病、死亡和生存的人群基线数据。
- 胶质母细胞瘤和脑膜瘤的占比数据有助于临床资源配置和疾病认知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control (CDC) and National Cancer Institute (NCI), is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors (malignant and non-malignant) and supersedes all previous CBTRUS reports in terms of completeness and accuracy. All rates (incidence and mortality) are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 23.79 (Malignant AAAIR=7.08, non-Malignant AAAIR=16.71). This rate was higher in females compared to males (26.31 versus 21.09), Blacks compared to Whites (23.88 versus 23.83), and non-Hispanics compared to Hispanics (24.23 versus 21.48). The most commonly occurring malignant brain and other CNS tumor was glioblastoma (14.5% of all tumors), and the most common non-malignant tumor was meningioma (38.3% of all tumors). Glioblastoma was more common in males, and meningioma was more common in females. In children and adolescents (age 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.14. An estimated 83,830 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US in 2020 (24,970 malignant and 58,860 non-malignant). There were 81,246 deaths attributed to malignant brain and other CNS tumors between 2013 and 2017. This represents an average annual mortality rate of 4.42. The 5-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 23.5% and for a non-malignant brain and other CNS tumor was 82.4%.
引用
- Ostrom QT, Patil N, Cioffi G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol. 2020. PMID: 33123732. doi:10.1093/neuonc/noaa200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。